Ranbaxy said on Thursday that it has signed an exclusive licensing agreement with US-based Atrix Laboratories to develop and market prostrate cancer drug Eligard in India.
Sun gets RBI nod for transfer of Ranbaxy overseas investments.
India's antitrust regulator has approved Sun-Ranbaxy deal, subject to the companies divesting seven products.
Almost a year after announcing a $4 billion deal, Sun Pharmaceutical Industries on Tuesday said merger of Ranbaxy with itself has been 'consummated.'
Ranbaxy was asked to sell all products containing Leuprorelin which are marketed and supplied under brand name Eligard.
